Lecanemab and donanemab were hailed as ‘the beginning of the end’ of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness. Lecanemab and donanemab were hailed as ‘the beginning of the end’ of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.
Pressure grows on NHS to stump up for £60,000 ‘miracle’ dementia drugs as drug watchdog reopens talks to give it the green light
